Lyell Immunopharma (LYEL) Stock Price, News & Analysis

Company Overview

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers. Early-stage candidates utilize technologies aimed at epigenetic reprogramming of T cells to improve their ability to expand, traffic to tumor sites and maintain durable anti-tumor activity. Lyell partners with academic centers and contract research organizations to advance its lead programs through IND-enabling studies and into clinical trials.

Founded in 2017 and headquartered in South San Francisco, Lyell Immunopharma was established by a team of immunologists and cell therapy experts. The company has raised venture funding from leading life science investors and maintains research and manufacturing operations in the San Francisco Bay Area. Under the leadership of co-founder and CEO David Chang, Lyell is building a translational research engine designed to accelerate the discovery, development and manufacturing of engineered T cell products for patients with high-unmet-need cancers.

Key Stats

• Today's Range: $12.90 to $13.52
• 50-Day Range: $9.10 to $13.73
• 52-Week Range: $7.65 to $32.00
• Volume: 140,065 shs
• Average Volume: 46,007 shs
• Market Capitalization: $253.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Reduce

Lyell Immunopharma Stock Analysis - MarketRank™

Lyell Immunopharma scored higher than 37% of companies evaluated by MarketBeat, and ranked 705th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Lyell Immunopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Lyell Immunopharma has a consensus price target of $15.00, representing about 13.9% upside from its current price of $13.17.

Amount of Analyst Coverage

Lyell Immunopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lyell Immunopharma are expected to grow in the coming year, from ($0.78) to ($0.70) per share.

Price to Book Value per Share Ratio

Lyell Immunopharma has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.69% of the float of Lyell Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Lyell Immunopharma has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyell Immunopharma has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyell Immunopharma does not currently pay a dividend.

Dividend Growth

Lyell Immunopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.69% of the float of Lyell Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Lyell Immunopharma has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyell Immunopharma has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: N/A

News Sentiment

Lyell Immunopharma has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lyell Immunopharma this week, compared to 2 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lyell Immunopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,817.00 in company stock.

Percentage Held by Insiders

22.30% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LYEL Stock Analysis - Frequently Asked Questions

How have LYEL shares performed this year?

Lyell Immunopharma's stock was trading at $12.80 at the beginning of the year. Since then, LYEL stock has increased by 2.9% and is now trading at $13.17.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($2.89) earnings per share for the quarter, topping analysts' consensus estimates of ($3.80) by $0.91. The firm earned $0.01 million during the quarter, compared to analyst estimates of $0 million. Lyell Immunopharma had a negative net margin of 552,328.31% and a negative trailing twelve-month return on equity of 85.58%.

When did Lyell Immunopharma's stock split?

Shares of Lyell Immunopharma reverse split before market open on Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Lyell Immunopharma IPO?

Lyell Immunopharma (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

Who are Lyell Immunopharma's major shareholders?

Top institutional investors of Lyell Immunopharma include ARCH Venture Management LLC (9.48%), MWG Management Ltd. (5.25%), Foresite Capital Management IV LLC (5.18%) and Orland Properties Ltd (3.93%). Insiders that own company stock include Richard Klausner, Richard Klausner, Lynn Seely, Lynn Seely, Sumant Ramachandra, Gary K Lee, Stephen J Hill, Charles W Newton, Charles W Newton, Otis W Brawley and Otis W Brawley.
View institutional ownership trends.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lyell Immunopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LYEL
• CIK: 1806952
• Web: www.lyell.com
• Phone: 650-695-0677
• Fax: N/A
• Employees: 270
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Lyell Immunopharma: $15.00
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +12.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($24.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$342.99 million
• Net Margins: -552,328.31%
• Pretax Margin: -552,328.31%
• Return on Equity: -85.58%
• Return on Assets: -68.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.65
• Quick Ratio: 7.65

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 4,285.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $26.21 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 19,210,000
• Free Float: 14,927,000
• Market Cap: $257.13 million
• Optionable: Optionable
• Beta: -0.19